Novo Nordisk strikes second licensing deal since frosty capital-markets day
AI Summary
Novo Nordisk has secured its second licensing deal following a chilly response from investors during a recent capital markets day where the company outlined its long-term strategy. This move indicates the company's commitment to expanding its drug portfolio despite market skepticism. The deal underscores Novo Nordisk's strategy to leverage external partnerships to bolster its pipeline, which could be crucial for maintaining investor confidence and market competitiveness in the dynamic pharmaceutical industry.
Original Source
Read the full article at Marketwatch →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.